Soluble CD44 is a potential marker for the early detection of head and neck cancer

Elizabeth J Franzmann, Erika P. Reategui, Felipe Pedroso, Francisco G. Pernas, Baris M. Karakullukcu, Kermit L. Carraway, Kara Hamilton, Rakesh Singal, W. Jarrard Goodwin

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Introduction: Head and neck squamous cell carcinoma (HNSCC) is a devastating and deadly disease, largely because it is diagnosed in late stage. Cure rates, currently at 50%, could increase to >80% with early detection. In this study, we evaluate soluble CD44 (solCD44) as an early detection tool for HNSCC by determining whether it reliably distinguishes HNSCC from benign disease of the upper aerodigestive tract. Methods: We carried out the solCD44 ELISA on oral rinses from 102 patients with HNSCC and 69 control patients with benign diseases of upper aerodigestive tract to determine the sensitivity and specificity of the test for differentiating HNSCC from benign disease. Furthermore, we did a pilot study using methylation-specific PCR primers on oral rinses from 11 HNSCC patients with low solCD44 levels and 10 benign disease controls. Results: Mean salivary solCD44 levels were 24.4 ± 32.0 ng/mL for HNSCC patients (range, 0.99-201 ng/mL) and 9.9 ± 16.1 ng/mL (range, 0.73-124 ng/mL) for the patients with benign disease (P < 0.0001). Depending on cutoff point and HNSCC site, sensitivity ranged from 62% to 70% and specificity ranged from 75% to 88%. Nine of 11 HNSCC and 0 of 10 controls with low solCD44 levels showed hypermethylation of the CD44 promoter. Conclusions: SolCD44 is elevated in the majority of HNSCC and distinguishes cancer from benign disease with high specificity. Whereas the solCD44 test lacks sensitivity by itself, methylation status of the CD44 gene seems to complement the solCD44 test. Our pilot data indicate that, together, these markers will detect HNSCC with very high sensitivity and specificity.

Original languageEnglish
Pages (from-to)1348-1355
Number of pages8
JournalCancer Epidemiology Biomarkers and Prevention
Volume16
Issue number7
DOIs
StatePublished - Jul 1 2007

Fingerprint

Head and Neck Neoplasms
Early Detection of Cancer
Methylation
Carcinoma, squamous cell of head and neck
Sensitivity and Specificity
Enzyme-Linked Immunosorbent Assay
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Soluble CD44 is a potential marker for the early detection of head and neck cancer. / Franzmann, Elizabeth J; Reategui, Erika P.; Pedroso, Felipe; Pernas, Francisco G.; Karakullukcu, Baris M.; Carraway, Kermit L.; Hamilton, Kara; Singal, Rakesh; Goodwin, W. Jarrard.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 16, No. 7, 01.07.2007, p. 1348-1355.

Research output: Contribution to journalArticle

Franzmann, Elizabeth J ; Reategui, Erika P. ; Pedroso, Felipe ; Pernas, Francisco G. ; Karakullukcu, Baris M. ; Carraway, Kermit L. ; Hamilton, Kara ; Singal, Rakesh ; Goodwin, W. Jarrard. / Soluble CD44 is a potential marker for the early detection of head and neck cancer. In: Cancer Epidemiology Biomarkers and Prevention. 2007 ; Vol. 16, No. 7. pp. 1348-1355.
@article{394cf7acdd444845b1ec57817cafd877,
title = "Soluble CD44 is a potential marker for the early detection of head and neck cancer",
abstract = "Introduction: Head and neck squamous cell carcinoma (HNSCC) is a devastating and deadly disease, largely because it is diagnosed in late stage. Cure rates, currently at 50{\%}, could increase to >80{\%} with early detection. In this study, we evaluate soluble CD44 (solCD44) as an early detection tool for HNSCC by determining whether it reliably distinguishes HNSCC from benign disease of the upper aerodigestive tract. Methods: We carried out the solCD44 ELISA on oral rinses from 102 patients with HNSCC and 69 control patients with benign diseases of upper aerodigestive tract to determine the sensitivity and specificity of the test for differentiating HNSCC from benign disease. Furthermore, we did a pilot study using methylation-specific PCR primers on oral rinses from 11 HNSCC patients with low solCD44 levels and 10 benign disease controls. Results: Mean salivary solCD44 levels were 24.4 ± 32.0 ng/mL for HNSCC patients (range, 0.99-201 ng/mL) and 9.9 ± 16.1 ng/mL (range, 0.73-124 ng/mL) for the patients with benign disease (P < 0.0001). Depending on cutoff point and HNSCC site, sensitivity ranged from 62{\%} to 70{\%} and specificity ranged from 75{\%} to 88{\%}. Nine of 11 HNSCC and 0 of 10 controls with low solCD44 levels showed hypermethylation of the CD44 promoter. Conclusions: SolCD44 is elevated in the majority of HNSCC and distinguishes cancer from benign disease with high specificity. Whereas the solCD44 test lacks sensitivity by itself, methylation status of the CD44 gene seems to complement the solCD44 test. Our pilot data indicate that, together, these markers will detect HNSCC with very high sensitivity and specificity.",
author = "Franzmann, {Elizabeth J} and Reategui, {Erika P.} and Felipe Pedroso and Pernas, {Francisco G.} and Karakullukcu, {Baris M.} and Carraway, {Kermit L.} and Kara Hamilton and Rakesh Singal and Goodwin, {W. Jarrard}",
year = "2007",
month = "7",
day = "1",
doi = "10.1158/1055-9965.EPI-06-0011",
language = "English",
volume = "16",
pages = "1348--1355",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Soluble CD44 is a potential marker for the early detection of head and neck cancer

AU - Franzmann, Elizabeth J

AU - Reategui, Erika P.

AU - Pedroso, Felipe

AU - Pernas, Francisco G.

AU - Karakullukcu, Baris M.

AU - Carraway, Kermit L.

AU - Hamilton, Kara

AU - Singal, Rakesh

AU - Goodwin, W. Jarrard

PY - 2007/7/1

Y1 - 2007/7/1

N2 - Introduction: Head and neck squamous cell carcinoma (HNSCC) is a devastating and deadly disease, largely because it is diagnosed in late stage. Cure rates, currently at 50%, could increase to >80% with early detection. In this study, we evaluate soluble CD44 (solCD44) as an early detection tool for HNSCC by determining whether it reliably distinguishes HNSCC from benign disease of the upper aerodigestive tract. Methods: We carried out the solCD44 ELISA on oral rinses from 102 patients with HNSCC and 69 control patients with benign diseases of upper aerodigestive tract to determine the sensitivity and specificity of the test for differentiating HNSCC from benign disease. Furthermore, we did a pilot study using methylation-specific PCR primers on oral rinses from 11 HNSCC patients with low solCD44 levels and 10 benign disease controls. Results: Mean salivary solCD44 levels were 24.4 ± 32.0 ng/mL for HNSCC patients (range, 0.99-201 ng/mL) and 9.9 ± 16.1 ng/mL (range, 0.73-124 ng/mL) for the patients with benign disease (P < 0.0001). Depending on cutoff point and HNSCC site, sensitivity ranged from 62% to 70% and specificity ranged from 75% to 88%. Nine of 11 HNSCC and 0 of 10 controls with low solCD44 levels showed hypermethylation of the CD44 promoter. Conclusions: SolCD44 is elevated in the majority of HNSCC and distinguishes cancer from benign disease with high specificity. Whereas the solCD44 test lacks sensitivity by itself, methylation status of the CD44 gene seems to complement the solCD44 test. Our pilot data indicate that, together, these markers will detect HNSCC with very high sensitivity and specificity.

AB - Introduction: Head and neck squamous cell carcinoma (HNSCC) is a devastating and deadly disease, largely because it is diagnosed in late stage. Cure rates, currently at 50%, could increase to >80% with early detection. In this study, we evaluate soluble CD44 (solCD44) as an early detection tool for HNSCC by determining whether it reliably distinguishes HNSCC from benign disease of the upper aerodigestive tract. Methods: We carried out the solCD44 ELISA on oral rinses from 102 patients with HNSCC and 69 control patients with benign diseases of upper aerodigestive tract to determine the sensitivity and specificity of the test for differentiating HNSCC from benign disease. Furthermore, we did a pilot study using methylation-specific PCR primers on oral rinses from 11 HNSCC patients with low solCD44 levels and 10 benign disease controls. Results: Mean salivary solCD44 levels were 24.4 ± 32.0 ng/mL for HNSCC patients (range, 0.99-201 ng/mL) and 9.9 ± 16.1 ng/mL (range, 0.73-124 ng/mL) for the patients with benign disease (P < 0.0001). Depending on cutoff point and HNSCC site, sensitivity ranged from 62% to 70% and specificity ranged from 75% to 88%. Nine of 11 HNSCC and 0 of 10 controls with low solCD44 levels showed hypermethylation of the CD44 promoter. Conclusions: SolCD44 is elevated in the majority of HNSCC and distinguishes cancer from benign disease with high specificity. Whereas the solCD44 test lacks sensitivity by itself, methylation status of the CD44 gene seems to complement the solCD44 test. Our pilot data indicate that, together, these markers will detect HNSCC with very high sensitivity and specificity.

UR - http://www.scopus.com/inward/record.url?scp=34447517331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447517331&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-06-0011

DO - 10.1158/1055-9965.EPI-06-0011

M3 - Article

C2 - 17627000

AN - SCOPUS:34447517331

VL - 16

SP - 1348

EP - 1355

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 7

ER -